S.jayarajan Nelson

S.jayarajan Nelson's AcademicInfluence.com Rankings

S.jayarajan Nelson

Engineering

#5996

World Rank

#7287

Historical Rank

Cybernetics

#110

World Rank

#116

Historical Rank

Biomedical Engineering

#492

World Rank

#502

Historical Rank

engineering Degrees

Download Badge

Engineering

Why Is S.jayarajan Nelson Influential?

(Suggest an Edit or Addition)

(See a Problem?)

S.jayarajan Nelson's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Metabolic Imaging of Patients with Prostate Cancer Using Hyperpolarized [1-13C]Pyruvate (2013) (1024)
Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma (2014) (954)
Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. (1996) (623)
Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging--clinicopathologic study. (1999) (584)
Clinical proton MR spectroscopy in central nervous system disorders. (2013) (491)
Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. (2008) (484)
Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. (2015) (438)
Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. (2005) (431)
Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens. (2001) (376)
Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer (2002) (371)
Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. (1999) (351)
Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. (2002) (274)
Evaluation of left ventricular volume and mass with breath-hold cine MR imaging. (1993) (266)
Quantitative in vivo magnetic resonance imaging of multiple sclerosis at 7 Tesla with sensitivity to iron (2008) (265)
MR-spectroscopy guided target delineation for high-grade gliomas. (2001) (263)
Hyperpolarized 13C MRI: Path to Clinical Translation in Oncology (2018) (255)
Measurement of brain glutamate using TE‐averaged PRESS at 3T (2004) (239)
Differentiation of Glioblastoma Multiforme and Single Brain Metastasis by Peak Height and Percentage of Signal Intensity Recovery Derived from Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging (2007) (238)
Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy. (1995) (225)
Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. (2005) (220)
13C-pyruvate imaging reveals alterations in glycolysis that precede c-Myc-induced tumor formation and regression. (2011) (212)
Improved water and lipid suppression for 3D PRESS CSI using rf band selective inversion with gradient dephasing (basing) (1997) (212)
Hyperpolarized C‐13 spectroscopic imaging of the TRAMP mouse at 3T—Initial experience (2007) (205)
A serial study of new MS lesions and the white matter from which they arise (1998) (203)
Methodological consensus on clinical proton MRS of the brain: Review and recommendations (2019) (202)
Survival analysis in patients with glioblastoma multiforme: Predictive value of choline‐to‐n‐acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume (2004) (197)
In vivo 13carbon metabolic imaging at 3T with hyperpolarized 13C‐1‐pyruvate (2007) (196)
Compressed sensing for resolution enhancement of hyperpolarized 13C flyback 3D-MRSI. (2008) (194)
Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR‐MAS spectroscopy of biopsy tissues (2008) (193)
Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer. (2000) (191)
Analysis of volume MRI and MR spectroscopic imaging data for the evaluation of patients with brain tumors (2001) (188)
Development of a robust method for generating 7.0 T multichannel phase images of the brain with application to normal volunteers and patients with neurological diseases (2008) (179)
Serial proton magnetic resonance spectroscopy imaging of glioblastoma multiforme after brachytherapy. (1997) (177)
Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging. (2012) (175)
In vivo molecular imaging for planning radiation therapy of gliomas: An application of 1H MRSI (2002) (175)
Hippocampal CA1 apical neuropil atrophy in mild Alzheimer disease visualized with 7-T MRI (2010) (173)
Kinetic modeling of hyperpolarized 13C1-pyruvate metabolism in normal rats and TRAMP mice. (2010) (171)
Hyperpolarized 13C magnetic resonance metabolic imaging: application to brain tumors. (2010) (171)
Serial proton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgery. (2001) (171)
Fast dynamic 3D MR spectroscopic imaging with compressed sensing and multiband excitation pulses for hyperpolarized 13C studies (2011) (170)
Dynamic susceptibility-weighted perfusion imaging of high-grade gliomas: characterization of spatial heterogeneity. (2005) (169)
Magnetic Resonance of 2-Hydroxyglutarate in IDH1-Mutated Low-Grade Gliomas (2012) (168)
Serial evaluation of patients with brain tumors using volume MRI and 3D 1H MRSI (1999) (166)
Localizing prostate cancer in the presence of postbiopsy changes on MR images: role of proton MR spectroscopic imaging. (1998) (166)
Multi-compound polarization by DNP allows simultaneous assessment of multiple enzymatic activities in vivo. (2010) (161)
Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging. (1996) (157)
Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy. (2010) (155)
Double spin-echo sequence for rapid spectroscopic imaging of hyperpolarized 13C. (2007) (154)
Multivoxel Magnetic Resonance Spectroscopy of Brain Tumors1 (2003) (154)
3D MRSI for resected high-grade gliomas before RT: tumor extent according to metabolic activity in relation to MRI. (2004) (152)
Quantitative apparent diffusion coefficients and T2 relaxation times in characterizing contrast enhancing brain tumors and regions of peritumoral edema (2005) (149)
3D compressed sensing for highly accelerated hyperpolarized 13C MRSI with in vivo applications to transgenic mouse models of cancer (2010) (149)
Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy (2008) (148)
Correlation of magnetic resonance spectroscopic and growth characteristics within Grades II and III gliomas. (2007) (145)
Multivoxel magnetic resonance spectroscopy of brain tumors. (2003) (144)
Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. (2009) (139)
Phased array detectors and an automated intensity‐correction algorithm for high‐resolution MR imaging of the human brain (1995) (138)
Measurement of in vivo multi-component T2 relaxation times for brain tissue using multi-slice T2 prep at 1.5 and 3 T. (2006) (137)
Detection of locally recurrent prostate cancer after cryosurgery: evaluation by transrectal ultrasound, magnetic resonance imaging, and three-dimensional proton magnetic resonance spectroscopy. (1996) (126)
Pulse sequence for dynamic volumetric imaging of hyperpolarized metabolic products. (2008) (124)
Time‐dependent effects of hormone‐deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging (2001) (123)
Development of methods and feasibility of using hyperpolarized carbon‐13 imaging data for evaluating brain metabolism in patient studies (2018) (122)
Detection of early response to temozolomide treatment in brain tumors using hyperpolarized 13C MR metabolic imaging (2011) (121)
A preliminary study of the prognostic value of proton magnetic resonance spectroscopic imaging in gamma knife radiosurgery of recurrent malignant gliomas. (2000) (119)
Metabolic imaging of low-grade gliomas with three-dimensional magnetic resonance spectroscopy. (2002) (119)
Imaging considerations for in vivo 13C metabolic mapping using hyperpolarized 13C‐pyruvate (2009) (119)
MR spectroscopic imaging of glutathione in the white and gray matter at 7 T with an application to multiple sclerosis. (2010) (118)
Analysis of the spatial characteristics of metabolic abnormalities in newly diagnosed glioma patients (2002) (117)
Clinical application of BASING and spectral/spatial water and lipid suppression pulses for prostate cancer staging and localization by in vivo 3D 1H magnetic resonance spectroscopic imaging (2000) (117)
Non-invasive in vivo assessment of IDH1 mutational status in glioma (2013) (115)
Comparison of relative cerebral blood volume and proton spectroscopy in patients with treated gliomas. (2000) (115)
Perfusion, diffusion and spectroscopy values in newly diagnosed cerebral gliomas (2006) (115)
Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma. (2009) (114)
Assessment of metastatic cervical adenopathy using dynamic contrast-enhanced MR imaging. (2003) (114)
Imaging Glioblastoma Multiforme (2003) (114)
Genetic variation influences glutamate concentrations in brains of patients with multiple sclerosis. (2010) (111)
Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM (2009) (109)
Current and Potential Applications of Clinical 13C MR Spectroscopy (2008) (105)
Longitudinal multivoxel MR spectroscopy study of pediatric diffuse brainstem gliomas treated with radiotherapy. (2004) (105)
Hyperpolarized 13C MR spectroscopic imaging can be used to monitor Everolimus treatment in vivo in an orthotopic rodent model of glioblastoma (2012) (102)
Identification of MRI and 1H MRSI parameters that may predict survival for patients with malignant gliomas (2004) (98)
Feasibility of using hyperpolarized [1-13C]lactate as a substrate for in vivo metabolic 13C MRSI studies. (2008) (98)
Surface coil MR imaging of the human brain with an analytic reception profile correction (1995) (96)
Three-dimensional magnetic resonance spectroscopic imaging of histologically confirmed brain tumors. (2001) (93)
Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1 (2017) (93)
Proton spectroscopic imaging of the human brain using phased array detectors (1995) (92)
Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide (2016) (92)
Investigation of tumor hyperpolarized [1‐13C]‐pyruvate dynamics using time‐resolved multiband RF excitation echo‐planar MRSI (2010) (89)
Volume MRI and MRSI techniques for the quantitation of treatment response in brain tumors: Presentation of a detailed case study (1997) (88)
High‐Resolution Phased‐Array MRI of the Human Brain at 7 Tesla: Initial Experience in Multiple Sclerosis Patients (2010) (87)
Proton magnetic resonance spectroscopy imaging in the evaluation of patients undergoing gamma knife surgery for Grade IV glioma. (2004) (86)
Assessment of therapeutic response and treatment planning for brain tumors using metabolic and physiological MRI (2011) (85)
High spatial resolution 1H‐MRSI and segmented MRI of cortical gray matter and subcortical white matter in three regions of the human brain (1999) (84)
Relationship of MR-derived lactate, mobile lipids, and relative blood volume for gliomas in vivo. (2005) (84)
Moderating Effects of Coping on the Relationship Between Stress and the Development of New Brain Lesions in Multiple Sclerosis (2002) (83)
In vivo evidence of glutamate toxicity in multiple sclerosis (2014) (82)
SIVIC: Open-Source, Standards-Based Software for DICOM MR Spectroscopy Workflows (2013) (82)
7-Tesla susceptibility-weighted imaging to assess the effects of radiotherapy on normal-appearing brain in patients with glioma. (2012) (81)
Childhood adrenoleukodystrophy: assessment with proton MR spectroscopy. (1993) (80)
DNP-Hyperpolarized 13C Magnetic Resonance Metabolic Imaging for Cancer Applications (2008) (79)
Directional diffusion in relapsing‐remitting multiple sclerosis: A possible in vivo signature of Wallerian degeneration (2003) (79)
Patterns of recurrence analysis in newly diagnosed glioblastoma multiforme after three-dimensional conformal radiation therapy with respect to pre-radiation therapy magnetic resonance spectroscopic findings. (2007) (79)
Multislice Brain Myelin Water Fractions at 3T in Multiple Sclerosis (2007) (79)
Free magnesium levels in normal human brain and brain tumors: 31P chemical-shift imaging measurements at 1.5 T. (1991) (78)
Improved solvent suppression and increased spatial excitation bandwidths for three‐dimensional press CSI using phase‐compensating spectral/spatial spin‐echo pulses (1997) (78)
Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed glioma (2009) (78)
Chemical shift imaging of human brain: axial, sagittal, and coronal P-31 metabolite images. (1990) (74)
A serial in vivo 7T magnetic resonance phase imaging study of white matter lesions in multiple sclerosis (2013) (74)
Computer-aided detection of radiation-induced cerebral microbleeds on susceptibility-weighted MR images☆ (2013) (73)
In Vivo Carbon-13 Dynamic MRS and MRSI of Normal and Fasted Rat Liver with Hyperpolarized 13C-Pyruvate (2009) (72)
Metabolic Profiling of IDH Mutation and Malignant Progression in Infiltrating Glioma (2017) (71)
Hyperpolarized [1-13C] glutamate: a metabolic imaging biomarker of IDH1 mutational status in glioma. (2014) (71)
High spatial resolution and speed in MRSI (1997) (69)
Susceptibility-weighted MR imaging of radiation therapy-induced cerebral microbleeds in patients with glioma: a comparison between 3T and 7T (2014) (69)
TE-Averaged two-dimensional proton spectroscopic imaging of glutamate at 3 T (2006) (69)
Mechanisms of normal appearing corpus callosum injury related to pericallosal T1 lesions in multiple sclerosis using directional diffusion tensor and 1H MRS imaging (2004) (69)
Magnetic resonance spectroscopy markers of disease progression in multiple sclerosis. (2014) (65)
Dynamic susceptibility contrast perfusion imaging of radiation effects in normal‐appearing brain tissue: Changes in the first‐pass and recirculation phases (2005) (65)
Clinically feasible NODDI characterization of glioma using multiband EPI at 7 T (2015) (64)
Survival analysis in patients with newly diagnosed glioblastoma using pre- and postradiotherapy MR spectroscopic imaging. (2013) (64)
Shielded Microstrip Array for 7T Human MR Imaging (2010) (63)
Changes in pyruvate metabolism detected by magnetic resonance imaging are linked to DNA damage and serve as a sensor of temozolomide response in glioblastoma cells. (2014) (60)
Ultrashort echo time and zero echo time MRI at 7T (2016) (59)
Registration of images from sequential MR studies of the brain (1994) (59)
A comparative study of myo-inositol quantification using LCmodel at 1.5 T and 3.0 T with 3 D 1H proton spectroscopic imaging of the human brain. (2004) (59)
Investigation of analysis methods for hyperpolarized 13C‐pyruvate metabolic MRI in prostate cancer patients (2018) (58)
Multi-channel metabolic imaging, with SENSE reconstruction, of hyperpolarized [1-(13)C] pyruvate in a live rat at 3.0 tesla on a clinical MR scanner. (2011) (56)
Comparison of T1 and T2 metabolite relaxation times in glioma and normal brain at 3T (2008) (56)
Magnetic resonance spectroscopic imaging (2004) (55)
A phase I trial of solubilized DR2:MBP84-102 (AG284) in multiple sclerosis (2000) (54)
Characterization of untreated gliomas by magnetic resonance spectroscopic imaging. (2002) (53)
GRAPPA-based susceptibility-weighted imaging of normal volunteers and patients with brain tumor at 7 T. (2009) (52)
A longitudinal study of ventricular volume in early relapsing-remitting multiple sclerosis (2000) (52)
Translation of Carbon‐13 EPI for hyperpolarized MR molecular imaging of prostate and brain cancer patients (2018) (52)
Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma (2018) (51)
Analysis of hyperpolarized dynamic 13C lactate imaging in a transgenic mouse model of prostate cancer. (2010) (51)
MRI lesion volume heterogeneity in primary progressive MS in relation with axonal damage and brain atrophy (2003) (50)
Characterization of metabolites in infiltrating gliomas using ex vivo 1H high-resolution magic angle spinning spectroscopy (2014) (50)
Imaging of brain tumors after therapy. (1999) (49)
Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma. (2011) (48)
Advanced magnetic resonance spectroscopic neuroimaging: Experts' consensus recommendations (2020) (48)
Apparent diffusion coefficient and fractional anisotropy of newly diagnosed grade II gliomas (2009) (46)
Generation of hyperpolarized substrates by secondary labeling with [1,1-13C] acetic anhydride (2009) (45)
In vivo 31P MR spectral patterns and reproducibility in cancer patients studied in a multi‐institutional trial (2006) (45)
Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM. (2010) (43)
T1 and T2 Metabolite Relaxation Times in Normal Brain at 3T and 7T (2013) (43)
Serial analysis of imaging parameters in patients with newly diagnosed glioblastoma multiforme. (2011) (43)
1H spectroscopic imaging of human brain at 3 Tesla: Comparison of fast three‐dimensional magnetic resonance spectroscopic imaging techniques (2009) (42)
Super-Resolution Track Density Imaging of Glioblastoma: Histopathologic Correlation (2013) (42)
Technique development of 3D dynamic CS‐EPSI for hyperpolarized 13C pyruvate MR molecular imaging of human prostate cancer (2018) (41)
Short‐echo three‐dimensional H‐1 MR spectroscopic imaging of patients with glioma at 7 tesla for characterization of differences in metabolite levels (2015) (41)
Registration of magnetic resonance spectroscopic imaging to computed tomography for radiotherapy treatment planning. (2001) (41)
Evaluating metabolites in patients with major depressive disorder who received mindfulness-based cognitive therapy and healthy controls using short echo MRSI at 7 Tesla (2016) (40)
Implementation of 3 T Lactate-Edited 3D 1H MR Spectroscopic Imaging with Flyback Echo-Planar Readout for Gliomas Patients (2010) (40)
Two-dimensional 31P-chemical shift imaging of intramuscular heterogeneity in exercising human forearm muscle. (1992) (39)
Multi-Channel Microstrip Transceiver Arrays Using Harmonics for High Field MR Imaging in Humans (2012) (38)
Considerations in applying 3D PRESS H-1 brain MRSI with an eight-channel phased-array coil at 3 T. (2006) (38)
Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab (2014) (38)
Combined parallel and partial fourier MR reconstruction for accelerated 8‐channel hyperpolarized carbon‐13 in vivo magnetic resonance Spectroscopic imaging (MRSI) (2013) (38)
Supervised pattern recognition for the prediction of contrast-enhancement appearance in brain tumors from multivariate magnetic resonance imaging and spectroscopy (2008) (38)
Dynamic hyperpolarized carbon‐13 MR metabolic imaging of nonhuman primate brain (2014) (38)
Multiparametric characterization of grade 2 glioma subtypes using magnetic resonance spectroscopic, perfusion, and diffusion imaging. (2009) (38)
Single breath-holding scans of the abdomen using FISP and FLASH at 1.5 T. (1988) (37)
Advances in ultra-high field MRI for the clinical management of patients with brain tumors. (2011) (37)
Detection of localized changes in the metabolism of hyperpolarized gluconeogenic precursors 13C‐lactate and 13C‐pyruvate in kidney and liver (2017) (37)
MRI apparent diffusion coefficient reflects histopathologic subtype, axonal disruption, and tumor fraction in diffuse-type grade II gliomas. (2011) (36)
Challenges in dynamic contrast‐enhanced MRI imaging of cervical lymph nodes to detect metastatic disease (2003) (36)
Strategies for rapid in vivo 1H and hyperpolarized 13C MR spectroscopic imaging. (2013) (36)
Evaluation of heterogeneous metabolic profile in an orthotopic human glioblastoma xenograft model using compressed sensing hyperpolarized 3D 13C magnetic resonance spectroscopic imaging (2013) (35)
Simplified gamma-variate fitting of perfusion curves (2004) (34)
Potential Value of MR Spectroscopic Imaging for the Radiosurgical Management of Patients with Recurrent High-Grade Gliomas (2007) (33)
Alignment of volume MR images and high resolution [18F]fluorodeoxyglucose PET images for the evaluation of patients with brain tumors. (1997) (33)
1H‐MRSI of radiation effects in normal‐appearing white matter: Dose‐dependence and impact on automated spectral classification (2004) (33)
Rapid sequential injections of hyperpolarized [1-¹³C]pyruvate in vivo using a sub-kelvin, multi-sample DNP polarizer. (2013) (32)
Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme. (2010) (32)
Methodological standardization for a multi‐institutional in vivo trial of localized 31P MR spectroscopy in human cancer research. In vitro and normal volunteer studies (2004) (31)
Unsupervised segmentation of brain tissue in multivariate MRI (2010) (31)
Quantification of prostate MRSI data by model‐based time domain fitting and frequency domain analysis (2006) (31)
Analysis of Metabolic Indices in Regions of Abnormal Perfusion in Patients with High-Grade Glioma (2007) (31)
Quantitative measurement of cancer metabolism using stimulated echo hyperpolarized carbon‐13 MRS (2014) (31)
Intracranial tumors in children: small single-voxel proton MR spectroscopy using short- and long-echo sequences (1996) (30)
Probing the phosphatidylinositol 3‐kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low‐grade gliomas (2017) (29)
Feasibility of dynamic susceptibility contrast perfusion MR imaging at 3T using a standard quadrature head coil and eight‐channel phased‐array coil with and without SENSE reconstruction (2006) (28)
Imaging Tumor Metabolism Using In Vivo Magnetic Resonance Spectroscopy (2015) (28)
Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop. (2014) (27)
Association of early changes in 1H MRSI parameters with survival for patients with newly diagnosed glioblastoma receiving a multimodality treatment regimen (2016) (27)
Magnetic resonance analysis of malignant transformation in recurrent glioma (2016) (27)
The effects of anti-angiogenic therapy on the formation of radiation-induced microbleeds in normal brain tissue of patients with glioma. (2016) (27)
Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas (2017) (26)
3-D echo planar (1)HMRS imaging in MS: metabolite comparison from supratentorial vs. central brain. (2002) (26)
The unique impact of changes in normal appearing brain tissue on cognitive dysfunction in secondary progressive multiple sclerosis patients (2004) (26)
Serial analysis of 3D H-1 MRSI for patients with newly diagnosed GBM treated with combination therapy that includes bevacizumab (2016) (26)
3D sensitivity encoded ellipsoidal MR spectroscopic imaging of gliomas at 3T. (2009) (25)
A practical multinuclear transceiver volume coil for in vivo MRI/MRS at 7 T. (2012) (25)
3D 1H MRSI of brain tumors at 3.0 tesla using an eight‐channel phased‐array head coil (2007) (25)
Comparison between 8‐ and 32‐channel phased‐array receive coils for in vivo hyperpolarized 13C imaging of the human brain (2019) (25)
Brain lesion volume and neuropsychological function predict efficacy of treatment for depression in multiple sclerosis. (2003) (25)
Improved spatial coverage for brain 3D PRESS MRSI by automatic placement of outer‐volume suppression saturation bands (2011) (24)
Unaliasing lipid contamination for MR spectroscopic imaging of gliomas at 3T using sensitivity encoding (SENSE) (2006) (24)
Identifying malignant transformations in recurrent low grade gliomas using high resolution magic angle spinning spectroscopy (2012) (22)
Phased array 3D MR spectroscopic imaging of the brain at 7 T. (2008) (22)
Comparison of DSC‐MRI post‐processing techniques in predicting microvascular histopathology in patients newly diagnosed with GBM (2013) (22)
Relationship between choline and apparent diffusion coefficient in patients with gliomas (2008) (22)
Accelerated high‐bandwidth MR spectroscopic imaging using compressed sensing (2016) (22)
Advanced magnetic resonance imaging methods for planning and monitoring radiation therapy in patients with high-grade glioma. (2014) (21)
A dual-tuned quadrature volume coil with mixed λ/2 and λ/4 microstrip resonators for multinuclear MRSI at 7 T. (2012) (21)
A multislice sequence for 31P in Vivo Spectroscopy. 1D chemical-shift imaging with an adiabatic half-passage pulse (1989) (21)
T2 relaxation time histograms in multiple sclerosis. (2002) (21)
Semi-automated segmentation of brain tumor lesions in MR Images. (2006) (20)
Three‐dimensional J‐resolved H‐1 magnetic resonance spectroscopic imaging of volunteers and patients with brain tumors at 3T (2007) (20)
Corpus callosum axonal injury in multiple sclerosis measured by proton magnetic resonance spectroscopic imaging. (2004) (19)
Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. (2018) (19)
Simultaneous imaging of radiation‐induced cerebral microbleeds, arteries and veins, using a multiple gradient echo sequence at 7 Tesla (2015) (19)
Automated prescription of oblique brain 3D magnetic resonance spectroscopic imaging (2013) (18)
Using susceptibility-weighted imaging to determine response to combined anti-angiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiforme. (2013) (18)
High resolution T2‐weighted imaging of the human brain using surface coils and an analytical reception profile correction (1997) (17)
Spectroscopic imaging of the brain with phased-array coils at 3.0 T. (2006) (16)
High-sensitivity coil array for head and neck imaging: technical note. (2001) (16)
Multiscale, multimodal analysis of tumor heterogeneity in IDH1 mutant vs wild-type diffuse gliomas (2019) (15)
Comparison between Short and Long Echo Time Magnetic Resonance Spectroscopic Imaging at 3T and 7T for Evaluating Brain Metabolites in Patients with Glioma. (2017) (15)
Standardized, reproducible, high resolution global measurements of T1 relaxation metrics in cases of multiple sclerosis. (2003) (14)
Partial‐volume model for determining white matter and gray matter cerebral blood volume for analysis of gliomas (2006) (14)
Estimation of metabolite T1 relaxation times using tissue specific analysis, signal averaging and bootstrapping from magnetic resonance spectroscopic imaging data (2007) (14)
Elliptical magnetic resonance spectroscopic imaging with GRAPPA for imaging brain tumors at 3 T. (2009) (14)
A comparison of coil combination strategies in 3D multi‐channel MRSI reconstruction for patients with brain tumors (2018) (13)
Quantitative 7T Phase Imaging in Premanifest Huntington Disease (2014) (13)
Grid enabled magnetic resonance scanners for near real-time medical image processing (2006) (12)
Characterization of low‐grade gliomas using RGB color maps derived from ADC histograms (2009) (12)
Spatial characteristics of newly diagnosed grade 3 glioma assessed by magnetic resonance metabolic and diffusion tensor imaging. (2012) (12)
1H‐13C independently tuned radiofrequency surface coil applied for in vivo hyperpolarized MRI (2015) (11)
Magnetic resonance spectroscopic imaging. Evaluating responses to therapy for gliomas. (2004) (10)
Chemical shift separation with controlled aliasing for hyperpolarized 13C metabolic imaging (2015) (10)
Identifying Voxels at Risk for Progression in Glioblastoma Based on Dosimetry, Physiologic and Metabolic MRI (2017) (10)
Partially Parallel MR Spectroscopic Imaging of Gliomas at 3T (2006) (10)
Quantitative multi-modal MR imaging as a non-invasive prognostic tool for patients with recurrent low-grade glioma (2017) (10)
What is the role of MR spectroscopy in the evaluation and treatment of brain neoplasms? (1999) (9)
Partially-parallel, susceptibility-weighted MR imaging of brain vasculature at 7 Tesla using sensitivity encoding and an autocalibrating parallel technique (2006) (9)
Original contributions Feasibility of using hyperpolarized (1- 13 C)lactate as a substrate for in vivo metabolic 13 C MRSI studies (2008) (9)
Investigating tumor perfusion by hyperpolarized 13C MRI with comparison to conventional gadolinium contrast‐enhanced MRI and pathology in orthotopic human GBM xenografts (2017) (8)
Characterization of Metabolic, Diffusion, and Perfusion Properties in GBM: Contrast-Enhancing versus Non-Enhancing Tumor12 (2017) (8)
Correlation of Tumor Perfusion Between Carbon-13 Imaging with Hyperpolarized Pyruvate and Dynamic Susceptibility Contrast MRI in Pre-Clinical Model of Glioblastoma (2018) (8)
MR-Spectroscopy results in improved target delineation for high-grade gliomas (2000) (7)
Quantitative analysis of spatial distortions of diffusion techniques at 3T. (2010) (7)
Microbleed Detection in Traumatic Brain Injury at 3 T and 7 T : Comparing 2 D and 3 D Gradient-Recalled Echo ( GRE ) Imaging with Susceptibility-Weighted Imaging ( SWI ) (2008) (7)
Relationship of In Vivo MR Parameters to Histopathological and Molecular Characteristics of Newly Diagnosed, Nonenhancing Lower-Grade Gliomas1 (2018) (7)
Reliable in vivo lactate and lipid estimation in glioma patients (2003) (7)
In vivo T1 values of phosphorus metabolites in human liver and muscle determined at 1.5 T by chemical shift imaging. (1989) (7)
Fast magnetic resonance spectroscopic imaging at 3 Tesla using autocalibrating parallel technique (2006) (7)
Fully automated atlas‐based method for prescribing 3D PRESS MR spectroscopic imaging: Toward robust and reproducible metabolite measurements in human brain (2018) (7)
Early and Progressive Disease Marker in MS; results from a large cross-sectional spectroscopic imaging study at 3T (2007) (7)
International Workshop on Standardization in Clinical Magnetic Resonance Spectroscopy Measurements: proceedings and recommendations. (1994) (6)
Association of Diffusion and Anatomic Imaging Parameters with Survival for Patients with Newly Diagnosed Glioblastoma Participating in Two Different Clinical Trials1 (2015) (6)
BI-07HYPERPOLARIZED [1-13C] GLUTAMATE: A METABOLIC IMAGING BIOMARKER OF IDH1 MUTATIONAL STATUS IN GLIOMA. (2014) (6)
Monitoring Prostate Cancer Progression in A Transgenic Murine Model Using 3T Hyperpolarized 13 C MRSI (2007) (5)
Reliable estimate of lactate and lipid for newly-diagnosed gliomas patients using lactate-edited 3D 1H-MRSI with ellipsoidal k- space sampling (2003) (4)
Reliable and Reproducible GABA Measurements Using Automated Spectral Prescription at Ultra-High Field (2017) (4)
Gliomas classification by multivariate analysis of in vivo MRI/MRSI data based on recursive partitioning tree and discriminant analysis (2002) (4)
Detection of significant features and statistical analysis of 2D and 3D images of 31p metabolites (1992) (4)
Proton Magnetic Resonance Spectroscopy in Assessing Axonal Loss in the Corpus Callosum Related with Volume of Regional T1 Lesion Load in Multiple Sclerosis (2001) (3)
Recurrent tumor and treatment-induced effects have different MR signatures in contrast enhancing and non-enhancing lesions of high-grade gliomas. (2019) (3)
Integrated Systems and Technologies Hyperpolarized [ 1-13 C ] Glutamate : A Metabolic Imaging Biomarker of IDH 1 Mutational Status in Glioma (2014) (3)
MR Spectroscopy Markers of Disease Progression in Multiple Sclerosis: A Clinical Validation Study (PL01.002) (2012) (3)
Neurovascular and Immuno-Imaging: From Mechanisms to Therapies. Proceedings of the Inaugural Symposium (2016) (3)
Comparison of glioma sub-populations using in-vivo ADC values and ex-vivo 1 H HR-MAS spectroscopy (2009) (3)
Presence of 2-Hydroxyglutarate in IDH 1 mutated low-grade glioma using ex vivo proton HR-MAS spectroscopy (2010) (2)
Automated Prescription and Reconstruction of Brain MR Spectroscopy Data for Rapid Integration into the Clinical Workflow (2017) (2)
GENO-25HYPERMUTATION AND MALIGNANT PROGRESSION IN AN EXPANDED COHORT OF TEMOZOLOMIDE-TREATED LOW-GRADE GLIOMA PATIENTS (2015) (2)
Spectroscopic Imaging of 1 H at 3 T : Comparing SNR between Traditional Phase Encoding and Echo-Planar Techniques in the Human Brain (2005) (2)
COMP-05. EVALUATION OF A DEEP LEARNING ARCHITECTURE FOR MRI PREDICTION OF IDH, 1p19q AND TERT IN GLIOMA PATIENTS (2018) (2)
Imaging biomarkers of ramucirumab and olaratumab in patients with recurrent glioblastoma. (2013) (2)
2873 Quantitative susceptibility mapping of Huntington ’ s disease at 7 Tesla (2013) (2)
USE OF PROTON MAGNETIC RESONANCE SPECTROSCOPIC IMAGING DATA IN PLANNING FOCAL RADIATION THERAPIES FOR BRAIN TUMORS (2011) (2)
Magnetic resonance spectroscopy guided integrated boost irradiation for high grade gliomas using IMRT (2000) (2)
Image-guided metabolomic analysis of 2-hydroxyglutarate in IDH-mutant gliomas (2012) (2)
A first-in-human phase I imaging study using hyperpolarized 1c-13 pyruvate (h-Py) in patients (pts) with localized prostate cancer (l-PCa). (2012) (2)
3D MRSI of Brain Tumors at 3 Tesla using an 8 Channel Phased Array Head Coil (2005) (2)
ADVANCED MR IMAGING METHODS FOR PLANNING AND MONITORING RADIATION THERAPY IN PATIENTS WITH HIGH GRADE GLIOMA (2016) (2)
International workshop on standardization in clinical MRS measurements: proceedings and recommendations. (1994) (2)
OMICS AND PROGNSTIC MARKERS (2013) (1)
Identifying Voxels at Risk for Progression in GBM Based on Dosimetry, Physiologic, and Metabolic MRI (2013) (1)
MR-spectroscopy imaging for resected high-grade gliomas prior to radiation therapy: tumor extent according to metabolic activity in relation to MRI (2002) (1)
Indication of oxidative stress in Multiple Sclerosis using proton MR spectroscopic imaging at 7T (2008) (1)
Assessing Tumor Response in GBM Following Concurrent Radiation and Chemotherapy by Means of Novel MR Based Imaging Methods Characterizing Metabolic and Physiologic Changes (2005) (1)
High Acceleration 3 D Compressed Sensing Hyperpolarized 13 C MRSI of a Transgenic Mouse Model of Liver Cancer (2008) (1)
Localization of Prostate Cancer After Hormone Ablation by MRI and 3 D 1 H MRSI : Case-Control Study with Pathologic Correlation (1999) (1)
Peak Detection and Quantification in NMR Spectra Using the PIQABLE Algorithm (1990) (1)
3T Brain Spectroscopy: Repeatability and Inter-subject Variability (2003) (1)
Hyperpolarized 13 C MR Metabolic Imaging Provides an Early Biomarker of MGMT Activity and Response to Temozolomide Treatment (2010) (1)
Considerations in applying 3-D PRESS 1-H MRSI for studies of patients with brain tumors at 3T relative to 1.5T (2005) (1)
MR spectroscopy of radiation effects in healthy brain tissue following radiotherapy (2003) (1)
Prognostic value of pre-gamma knife MR spectroscopic imaging for treatment strategy and clinical outcome (2004) (1)
of Metabolic, Diffusion, and Perfusion Properties in GBM: Contrast-Enhancing versus Non-Enhancing Tumor. (2017) (1)
Abstract 3520: Imaging parameters and molecular correlates as predictive markers of treatment response to mTOR inhibition in adults with recurrent low-grade gliomas. (2013) (1)
DIPG-16. NONINVASIVE ASSESSMENT OF TREATMENT RESPONSE FOR DIFFUSE INTRINSIC PONTINE GLIOMA USING HYPERPOLARIZED 13C METABOLIC IMAGING (2017) (1)
Automatic Prescription of 3 D MRSI with Optimal Coverage and Outer Volume Suppression (2008) (1)
EFFECTS OF TREATMENT ON THE METABOLIC CHARACTERISTICS OF GRADE 2 AND GRADE 3 GLIOMAS (2011) (1)
724 MULTIVARIATE PATTERN ANALYSIS FOR IDENTIFICATION OF METABOLITES THAT ARE PREDICTIVE OF MALIGNANT TRANSFORMATION IN GLIOMAS USING HRMAS SPECTRA FROM IMAGE GUIDED TISSUE SAMPLES (2010) (1)
Using 7T susceptibility-weighted imaging to aid in the characterization of high-grade gliomas (2008) (1)
Metabolome heterogeneity in the isolates of entomopathogenic fungus, Beauveria bassiana(Balsamo) Vuillemin (2019) (1)
Metabolic imaging by means of 3D MR-spectroscopy for low-grade gliomas (2001) (1)
NI-61VOLUMETRIC H-1 MR METABOLIC IMAGING FOR DEFINITION OF LESION BURDEN AND PREDICTION OF OUTCOME FOR PATIENTS WITH NEWLY DIAGNOSED GBM (2014) (1)
Improving SNR and Spatial Coverage for 7 T DTI of Human Brain Tumor Using B 1 Mapping and Multiband Acquisition (2012) (1)
Tumor cell phenotype and heterogeneity differences in IDH1 mutant vs wild-type gliomas (2019) (1)
Tumor Regrowth Between Surgery and Initiation of Radiation Therapy in Patients With Newly Diagnosed GBM (2007) (1)
NCOG-14. NEUROCOGNITIVE FUNCTION AND QUALITY OF LIFE IN STABLE GRADE II AND III GLIOMA PATIENTS (2017) (0)
NIMG-11. DIFFERENTIATING TREATMENT-INDUCED EFFECTS FROM TRUE RECURRENT HIGH GRADE GLIOMA USING MULTIPARAMETRIC MRI TECHNIQUES (2018) (0)
MR imaging parameters are indicative of malignant transformation for low grade gliomas (2011) (0)
Application of 3 D High-resolution Multi-echo TOF-SWI Acquisition in Radiation-induced Cerebral Microbleeds at 3 T (2014) (0)
Evaluation of Heterogeneous Metabolic Profile in an Orthotopic Human Glioblastoma Xenograft Model Using 3 D Compressed Sensing Hyperpolarized 13 C MRSI (2010) (0)
In This Issue (2009) (0)
GENT-05. DELETION OR AMPLIFICATION OF MUTANT IDH1 IS ASSOCIATED WITH EXTREME DNA HYPOMETHYLATION AND MALIGNANT PROGRESSION (2016) (0)
NIMG-08. REPRODUCIBILITY OF HYPERPOLARIZED C-13 METABOLIC IMAGING IN PATIENTS WITH GLIOMA (2018) (0)
A computer-aided Detection of Cerebral Microbleeds on Minimum Intensity Projection MR images of SWI (2012) (0)
C-Pyruvate Studies in Prostate Cancer Patients (2009) (0)
ACTR-32. A PROSPECTIVE PHASE II STUDY OF EVEROLIMUS FOR RECURRENT ADULT LOW GRADE GLIOMAS (2016) (0)
MULTIVARIATE PATTERN ANALYSIS OF IN VIVO MR IMAGING PARAMETERS FOR DETECTING TRANSFORMATIONS TO A HIGHER GRADE IN PATIENTS WITH RECURRENT LOW GRADE GLIOMAS (2011) (0)
Differentiation of Low-Grade Glioma Subtypes Using Mutiparametric MR Data (2008) (0)
Determining Voxel Response to Radiation Therapy in Glioblastoma Using Integrated Dosimetry, Diffusion, Perfusion, and Spectra (2014) (0)
NIMG-53. POST-SURGICAL, RESIDUAL ENHANCING TUMOR VOLUME IS PROGNOSTIC FOR OVERALL SURVIVAL IN NEWLY DIAGNOSED GLIOBLASTOMA: EVIDENCE FROM 1,458 PATIENTS POOLED FROM INTERNATIONAL TRIALS, SINGLE INSTITUTION DATABASES, AND MULTICENTER CONSORTIUMS (2017) (0)
Optimal K-space Sampling For Chemical Shift Imaging (1990) (0)
MR Spectroscopic Imaging : Application to Brain Tumors (2008) (0)
Longitudinal analysis of physiologic MRI parameters in patients with newly diagnosed glioblastoma multiforme to predict outcome. (2010) (0)
The differences of MR spectroscopic imaging and MR diffusion weighted imaging parameters in different subtypes of grade 3 gliomas (2010) (0)
Improvement of magnetization transfer ratio in new gadolinium-enhanced lesions detected before and during therapy with interferon-β-1a (2001) (0)
GENE-47. A 3D ATLAS TO EVALUATE THE SPATIAL PATTERNING OF GENETIC ALTERATIONS AND TUMOR CELL STATES IN GLIOMA (2019) (0)
Dynamic Contrast Uptake in Cervical Lymph Nodes: Correlation with Biopsy (2000) (0)
Multivariate pattern analysis of anatomic, physiologic, and metabolic imaging data for improved management of patients with gliomas (2012) (0)
HG-117ASSESSING THE RESPONSE OF DIFFUSE INTRINSIC PONTINE GLIOMA TO PANOBINOSTAT USING HYPERPOLARIZED 13C MAGNETIC RESONANCE METABOLIC IMAGING (2016) (0)
Hormone Ablation of Localized Prostate Cancer : Effects of Duration of Therapy on Prostate Metabolism Demonstrated by 3 D ‘ H MR Spectroscopy (1999) (0)
A Comparison of Two Phase Correction Strategies in Multi-Channel MRSI Reconstruction (2009) (0)
Improved Temporal Resolution for Hyperpolarized C 3D Dynamic MRSI with Compressed Sensing (2009) (0)
Assessment of hypoxia in recurrent GBM with 18F-fluoromisonidazole PET, MRI and MRSI: Preliminary results (2012) (0)
Exploring Phase Contrast Mechanisms of Multiple Sclerosis Lesions at 7T (P6.113) (2015) (0)
Quantitative 7 T Phase Imaging in Presymptomatic Huntington ’ s Disease (2011) (0)
1-H MRSI in patients with relapsing multiple sclerosis at 7 Tesla (P6.121) (2015) (0)
Radiographic and Molecular Correlates of Progression in Patients with Recurrent Low-Grade Gliomas Treated with Everolimus Under a Phase II Clinical Trial (2014) (0)
EVEROLIMUS (RAD001) AND THE MTOR PATHWAY IN LOW-GRADE GLIOMAS (2014) (0)
In Vivo Monitoring of Rat Spinal Cord Metabolism Using Hyperpolarized Carbon-13 MR Spectroscopic Imaging (2016) (0)
Multi-Channel Spectroscopic Imaging Reconstruction Using Water-Referencing with Compressed Sensing (2010) (0)
NIMG-58. AUTOMATED APPROACH TO PREDICTING MALIGNANT TRANSFORMATIONS IN RECURRENT LOW-GRADE GLIOMAS USING EX VIVO SPECTROSCOPIC DATA (2016) (0)
EX VIVO METABOLIC SIGNATURES OF GLIOMAS BASED UPON TUMOR GRADE, IMAGING CHARACTERISTICS AND TREATMENT HISTORY (2014) (0)
In vivo T2 brain histogram in multiple sclerosis (2001) (0)
Short-echo spin-echo localization MRSI in gliomas at 7 Tesla (2010) (0)
Detection of Radiation Therapy Induced Cerebral Microbleeds in Gliomas : Does High Field Mean High Yield ? (2011) (0)
MR biomarker profile for infiltrative tumor region in malignant glioma (2010) (0)
Assessment of diffusion parameters in scans prior to progression in GBM patients following antiangiogenic therapy. (2010) (0)
NIMG-24. DIFFUSION MRI PRECURSORS TO PROGRESSION IN GRADE II AND III GLIOMA (2018) (0)
Re: A simple method for retrieving metal foreign objects from an MR imager. (1985) (0)
Magnetic Resonance SpectroscopyMarkers of Disease Progression inMultiple Sclerosis (2014) (0)
NI-40MR IMAGING AND SPECTROSCOPY PROVIDES INSIGHT INTO MALIGNANT TRANSFORMATION AND IDH-MUTATION STATUS IN DIFFUSE LOW-GRADE GLIOMA. (2014) (0)
1 Co-polarization of ( 1-13 C ) Pyruvate and 13 C Sodium Bicarbonate by Dynamic Nuclear Polarization allows Simultaneous Assessment of in vivo pH and Tumor Metabolism (2008) (0)
Characteristics of Recurrence in Glioblastoma Treated with Radiation and Anti-angiogenic Therapy using Integrated Dosimetry, Diffusion, Perfusion, and Spectra (2011) (0)
IMAGING BIOMARKERS OF MALIGNANT PROGRESSION OF DIFFUSE LOW-GRADE GLOMA (LGG). (2014) (0)
Novel Automated 3 D MRSI Acquisition with Whole Brain Slice Selection and Outer-Volume Suppression (2010) (0)
3059 Measurements of glutamatergic pathway in patients with schizophrenia using 7 T MRSI (2013) (0)
SPECTROSCOPIC STUDIES ( EPR , NMR ) MP 4 l APPLICATIONS OF MAGNETICALLY COUPLED RELAXATION SPECTROSCOPY TO UNDERSTANDING MAGNETIC RELAXATION IN TISSUES AND PROTEIN SYSTEMS (2005) (0)
GENE-33. THE 3D EVOLUTION AND IN VIVO GROWTH PATTERNS OF GLIOMA CELL POPULATIONS (2017) (0)
Using 7 T susceptibility-weighted imaging to aid in the characterization of high-grade gliomas (2007) (0)
Correlation of 1 H MRSI , rCBV , and ADC to Image Guided Biopsies of Human Brain Tumors (1999) (0)
Automation of spectroscopic scoring of prostate MRSI by a canonical analysis based classification (2006) (0)
NIMG-66. COMPARISON OF STEADY STATE AND DYNAMIC BRAIN METABOLISM BY USING 1H MRSI AND HYPERPOLARIZED [1-13C]PYRUVATE IMAGING IN PATIENTS WITH GLIOMA (2018) (0)
Metabolic characterization of glioma populations with emphasis on onco-metabolite 2-hydroxyglutarate (2010) (0)
NCOG-11. FEASIBILITY AND EFFICACY OF AN IPAD-BASED COGNITIVE REHABILITATION PROGRAM IN BRAIN TUMOR PATIENTS (2018) (0)
NI-79RAPID ASSESSMENT OF LESION VOLUMES FOR PATIENTS WITH GLIOMA USING THE SMARTBRUSH SOFTWARE PACKAGE. (2014) (0)
SURG-02. A NOVEL RISK MODEL TO DEFINE THE RELATIVE BENEFIT OF MAXIMAL EXTENT OF RESECTION WITHIN PROGNOSTIC GROUPS IN NEWLY DIAGNOSED GLIOBLASTOMA (2018) (0)
ATIM-22. PROGNOSTIC VALUE OF PTEN LOSS IN NEWLY DIAGNOSED GBM PATIENTS TREATED WITH AUTOLOGOUS HEAT SHOCK PROTEIN VACCINE (2018) (0)
Quantification of 31P NMR in vivo Spectra (1990) (0)
Integration of radiology and radiation oncology data for improved clinical management of brain tumor patients (2000) (0)
Imaging of Hypoxia in recurrent GBM using 18 F-fluoromisonidazole PET , MRI and MRSI (2011) (0)
Evaluation of metabolic heterogeneity in regions of contrast-enhancing versus non-enhancing GBM using 1 H HR-MAS spectroscopy (2012) (0)
prolifera-Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma (2009) (0)
WE‐D‐T‐6C‐04: MRI and MR Spectroscopic Imaging of Cancer Therapy Assessment (2005) (0)
Abstract B110: Early radiographic and physiologic changes in patients with recurrent low-grade gliomas treated with everolimus under a phase II clinical trial. (2011) (0)
Hippocampal neuropil atrophy in early Alzheimer's disease: A 7T MRI study (2010) (0)
7775 2 D-SPIRiT accelerated MRSI of the brain using different calibration regions at 7 T (2013) (0)
NIMG-32. 3D SHORT AND LONG ECHO TIME 1H MRSI IN PATIENTS WITH NON-ENHANCING GLIOMAS (2016) (0)
GE-15CLONAL EVOLUTION AND INTRATUMORAL HETEROGENEITY OF LOW-GRADE GLIOMA GENOMES (2014) (0)
Correlation Between Hyperpolarized 13 C MRSI and Perfusion Data from Dynamic Susceptibility Contrast MRI (2010) (0)
3869 Automated Kinetic Modeling of Perfusion and Metabolism Based on Dynamic Hyperpolarized 13 C Data With Open-Source SIVIC Software (2013) (0)
Quantification of microvascular leakage in malignant glioma and solitary brain metastasis using dynamic bolus tracking susceptibility perfusion MR imaging (2004) (0)
Longitudinal MRSI study in newly diagnosed Glioblastoma Multiforme (2010) (0)
RTHP-02. CHARACTERIZATION AND EVOLUTION OF RADIOTHERAPY-INDUCED VASCULAR INJURY AND CORRESPONDING CHANGES IN WHITE MATTER STRUCTURE: AN INVESTIGATIVE STUDY IN 125 PATIENTS WITH GLIOMAS (2017) (0)
Neurocognitive Function and Quality of Life in Stable Grade 2 and 3 Glioma Patients (P6.140) (2018) (0)
NIMG-43. APPLICATION OF AN ADVANCED DIFFUSION-WEIGHTED MRI TECHNIQUE TO CHARACTERIZE GLIOMA MICROSTRUCTURE AND RELATIONSHIP TO HISTOPATHOLOGY (2016) (0)
PDTB-05. DEVELOPING A NONINVASIVE IMAGING MARKER FOR ASSESSING THE RESPONSE OF DIFFUSE INTRINSIC PONTINE GLIOMA TO PANOBINOSTAT USING HYPERPOLARIZED CARBON-13 MR METABOLIC IMAGING (2016) (0)
Multi-echo Acquisition of 3 D TOF and SWI of Radiation-induced Cerebral Microbleeds at 7 T (2012) (0)
Development of an MR spectroscopic index to differentiate tumor from treatment induced gliosis (2008) (0)
New Hyperpolarized Carbon-13 MR Markers of Metabolism – Spin-Relaxation , Diffusion , and Kinetic Parameters (2012) (0)
NIMG-84. TUMOR LOCATION IS PROGNOSTIC FOR OVERALL SURVIVAL IN NEWLY DIAGNOSED GLIOBLASTOMA: EVIDENCE FROM 1,458 PATIENTS POOLED FROM INTERNATIONAL TRIALS, SINGLE INSTITUTION DATABASES, AND MULTICENTER CONSORTIUMS. (2017) (0)
NIMG-40. TUMOR PROGRESSION BETWEEN SURGERY AND INITIATION OF ADJUVANT CONCURRENT CHEMORADIATION IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS (2016) (0)
NIMG-42. RECURRENT TUMOR AND TREATMENT-INDUCED EFFECTS HAVE DIFFERENT MR SIGNATURES IN CONTRAST ENHANCING AND NON-ENHANCING LESIONS OF HIGH-GRADE GLIOMAS (2019) (0)
CLIN-NEURO-COGNITIVE (2012) (0)
An exploratory survival analysis of malignant glioma patients using pre-surgery MRI and 3 D 1 H-MRSI data with recursive partitioning (2002) (0)
Optimization of MRI for Breast Cancer Subtypes in Predicting Response to Neoadjuvant Chemotherapy (2014) (0)
Media and Book Reviews: Comprehensive Review in Clinical Neurology: A Multiple Choice Question Book for the Wards and Boards, First Edition (2013) (0)
BT-07MEASURING TUMOR METABOLISM IN DIFFUSE INTRINSIC PONTINE GIOMAS (DIPG) USING HYPERPOLARIZED CARBON-13 MR SPECTROSCOPIC IMAGING (2015) (0)
Cartesian and Elliptical GRAPPA Based Spectroscopic Imaging of Gliomas at 3 Tesla (2007) (0)
TH‐E‐ValB‐05: Analysis of Early Treatment Failure in Patients with Newly Diagnosed GBM Using Advanced MR Imaging (2006) (0)
Adjuvant temozolomide for low grade gliomas: Molecular and radiographic correlates of treatment response in a phase II clinical trial. (2016) (0)
ERRATUM (2018) (0)
NIMG-60. DIFFUSION IMAGING INTERPRETATION FOR GRADE 2 AND 3 GLIOMAS DEPENDS UPON NEW VS RECURRENT STATUS AND ENHANCING VS NON-ENHANCING STATUS (2016) (0)
Omission of Radiation Therapy for Low-Grade Gliomas: Molecular and Radiographic Correlates of Treatment Response and Disease Progression on a Phase 2 Clinical Trial of Adjuvant Temozolomide (2016) (0)
NIMG-65. IN VIVO DETECTION OF 2-HYDROXYGLUTARATE IN LOW-GRADE IDH-MUTANT GLIOMAS WITH STABLE DISEASE (2016) (0)
NIMG-48MR DIFFUSION PROFILES OF NON-ENHANCING LOWER-GRADE GLIOMAS (2015) (0)
In vivo detection of PI 3 K pathway inhibition by hyperpolarized 13 C MRSI at 14 Tesla (2009) (0)
Can Susceptibility-Weighted Imaging determine response to combined anti-angiogenic , cytotoxic , and radiation therapy in GBM patients ? (2009) (0)
Evaluating metabolites in patients with major depressive disorder who received cognitive therapy and healthy controls using short echo MRSI at 7 (2016) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With S.jayarajan Nelson?

S.jayarajan Nelson is affiliated with the following schools:

University of California, San Francisco

S.jayarajan Nelson's Academic­Influence.com Rankings

Why Is S.jayarajan Nelson Influential?

S.jayarajan Nelson's Published Works

Published Works

What Schools Are Affiliated With S.jayarajan Nelson?

S.jayarajan Nelson's AcademicInfluence.com Rankings